Therapeutic dendrimer

A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a dendrimer comprising:

• i) a core unit (C), wherein the core unit is:
• and
• ii) building units (BU), wherein the building unit are each:
• wherein the acyl group of each building unit provides a covalent attachment point for attachment to the core or to a previous generation building unit and wherein each nitrogen atom provides a covalent attachment point for covalent attachment to a subsequent generation building unit, a first terminal group or a second terminal group;
• wherein the core unit is covalently attached to two building units via amide linkages, each amide linkage being formed between a nitrogen atom present in the core unit and the carbon atom of an acyl group present in a building unit;
• the dendrimer being a five generation building unit dendrimer;
• wherein building units of different generations are covalently attached to one another via amide linkages formed between a nitrogen atom present in one building unit and the carbon atom of an acyl group present in another building unit;
• the dendrimer further comprising:
• iii) a plurality of first terminal groups (T1) each comprising a cabazitazel residue covalently attached to a diglycolyl linker group;
• and
• iv) a plurality of second terminal groups (T2) each comprising a PEG group having an average molecular weight in the range of from 1,000 to 2,500 Daltons;
• wherein at least one third of the nitrogen atoms present in outer building units are each covalently attached to a first terminal group;
• and
• at least one third of the nitrogen atoms present in outer building units are each covalently attached to a second terminal group;
• or a pharmaceutically acceptable salt thereof.